<DOC>
	<DOCNO>NCT01327885</DOCNO>
	<brief_summary>This randomize , open-label , multicenter , Phase 3 study compare efficacy safety eribulin dacarbazine subject advance soft tissue sarcoma disease progression within 6 month prior study enrolment follow standard therapy must include anthracycline , unless contraindicate least one additional regimen failure anthracycline .</brief_summary>
	<brief_title>Phase 3 Study Compare Efficacy Safety Eribulin With Dacarbazine Subjects With Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>1 . Histologically confirm diagnosis soft tissue sarcoma high intermediate grade one follow histological subtypes : Adipocytic sarcoma , include : Dedifferentiated Myxoid Round Cell Pleomorphic Leiomyosarcoma 2 . Documented evidence advance ( locally recurrent , locally advanced and/or metastatic ) adipocytic ( restricted subtypes list Inclusion 1 ) leiomyosarcoma , incurable surgery and/or radiotherapy . 3 . Subjects receive least two standard systematic regimen advance soft tissue sarcoma one must include anthracycline ( unless contraindicate ) . 4 . Radiographic evidence disease progression RECIST criterion last anticancer therapy within 6 month prior randomization . 5 . Presence measurable disease meeting follow criterion : At least one lesion great equal 1.0 cm longaxis diameter non lymph node great equal 1.5 cm shortaxis diameter lymph node serially measurable accord RECIST 1.1 use either computerized tomography magnetic resonance image panoramic closeup color photography . Lesions radiotherapy must show evidence progressive disease base RECIST 1.1 deem target lesion . 6 . Eastern Cooperative Oncology Group , performance status 0 , 1 2 . 7 . Adequate renal function define calculated creatinine clearance great 50 mL/min per Cockroft Gault formula . 8 . Adequate bone marrow function , define : Absolute neutrophil count ( ANC ) great equal 1,500/mm3 great equal 1.5 x 10^9/L . Platelet count great equal 100,000/mm3 great equal 100 x 10^9/L . Hemoglobin ( Hb ) great equal 10g/dL baseline ( blood transfusion , hematopoietic growth factor hematinics allow Prerandomization Phase correct Hb value less 10g/dL ) . 9 . Adequate liver function , define : Bilirubin le equal 1.5 time upper limit normal ( ULN ) except unconjugated hyperbilirubinemia Gilbert 's syndrome . Alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 time ULN . For total ALP great 3 time ULN , ALP liver isoenzyme must less equal 3 time ULN . 10 . All female subject consider childbearing potential unless postmenopausal ( least 12 month consecutive amenorrhea , appropriate age group without know suspected cause ) , sterilize surgically ( i.e. , bilateral tubal ligation great equal 1 menstrual cycle prior randomization , undergone hysterectomy and/or bilateral oophorectomy ) . Female subject childbearing potential must agree use two form highly effective contraception last menstrual period prior randomization ( use double barrier method describe two form highly effective contraception least one menstrual cycle ) , study treatment , 3 month final dose study treatment . Female subject exempt requirement subject practice total abstinence . If currently abstinent , subject must agree use double barrier method contraception , i.e. , condom occlusive cap ( diaphragm cervical/vault cap ) spermicide two form highly effective contraception least one menstrual cycle become sexually active study treatment 3 month final dose study treatment . Highly effective contraception include : Placement intrauterine device system , Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicide , Established hormonal contraceptive method : oral , injectable implant . Female subject use hormonal contraceptive must stable dose hormonal contraceptive product last menstrual period prior randomization , must continue use hormonal contraceptive product study treatment , 3 month first dose study treatment . Vasectomized partner confirm azoospermia . 11 . Male subject female partner childbearing potential ( defined Inclusion 10 ) , practice total abstinence , must agree use two form highly effective contraception last menstrual period female partner prior randomization ( use double barrier method describe two form highly effective contraception least one menstrual cycle ) , study treatment , 3 month ( 6 month receive dacarbazine ) final dose study treatment . If currently abstinent , must agree use double barrier method contraception become sexually active , two form highly effective contraception describe . 12 . Voluntary agreement provide write informed consent willingness ability comply aspects protocol . 13 . Males female age great equal 18 year time inform consent . 1 . Subjects receive anticancer therapy , include radiotherapy , cytotoxic , hormonal , biological ( include humanize antibody ) target agent within 21 day , five halflives drug ( whichever longer ) prior randomization . 2 . Subjects recover acute toxicity result prior anticancer therapy less equal Grade 1 , accord Common Terminology Criteria Adverse Events ( CTCAE ) , except peripheral neuropathy ( see Exclusion 6 ) alopecia . 3 . Subjects previously treat dacarbazine analogue temozolomide eribulin . 4 . Major surgery within 21 day prior randomization . 5 . Preexisting peripheral neuropathy great CTCAE Grade 2 . 6 . Significant cardiovascular impairment , define : Cardiac failure , New York Heart Association ( NYHA ) Class II accord NYHA Functional Classification , Unstable angina myocardial infarction within 6 month enrolment , Serious potentially lifethreatening arrhythmia . 7 . Subjects high probability Long QT Syndrome QTc interval prolongation equal 501 msec least two separate ECGs , follow correction electrolyte imbalance . 8 . Subjects known central nervous system metastasis . 9 . Any serious concomitant illness infectious disease require treatment , infectious disease require treatment , significant risk myelosuppressive complication associate chemotherapy . 10 . Any malignancy require treatment , show evidence recurrence ( except soft tissue sarcoma , nonmelanoma skin cancer , histologically confirm complete excision carcinoma situ ) 5 year prior randomization . 11 . Female subject must pregnant documented negative betahuman chorionic gonadotropin ( betahCG ) test minimum sensitivity 25 IU/L equivalent unit betahCG Screening Baseline , breastfeed . 12 . Hypersensitivity active substance , excipients eribulin drug product , dacarbazine , ( please refer dacarbazine prescribe information ) . 13 . Any medical condition , opinion PI designee , preclude participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>